Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 7:24 PM
Ignite Modification Date:
2025-12-24 @ 7:24 PM
NCT ID:
NCT01189903
Brief Summary:
1. Primary Endpoints
* Biomarker data suggestive of regorafenib-mediated inhibition of the RAS-RAF- MEK-ERK signal transduction pathway,of various tyrosine kinase receptors and/or of angiogenesis.
* Evaluation of potential relationships between biomarker data and clinical activity.
* Evaluation of a novel biomarker technology (Prometheus COPIA platform)
2. Secondary Endpoints
* Biomarker data suggestive of regorafenib-mediated effects on circulating rare cells.
* Comparison of tumor genetic profiles obtained using DNA isolated from plasma, tumor biopsies and circulating tumor cells.
* Patient safety data
* Pharmacokinetics of regorafenib
* Changes in tumor metabolic activity as measured by PET CT scan (optional)
Study:
NCT01189903
Study Brief:
Protocol Section:
NCT01189903